ArticleCancer cell2018
NRL and CRX Define Photoreceptor Identity and Reveal Subgroup-Specific Dependencies in Medulloblastoma.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer cell, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 48 papers.
0numbers the graph read from it
0cells of the map it votes in
48citing papers in PubMed
2.8field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
48 citing papers in PubMed, 74 citations in OpenAlex.
- CReP-mediated control of eIF2α phosphorylation is a critical node in MYC-driven medulloblastoma.Nature communications · 2026Article
- A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies.Cancer cell · 2026Article
- Multiomic integration reveals tumoral heterogeneity of lipid dependence within lethal group 3 medulloblastoma.Cancer cell · 2026Article
- Epigenetic regulation in medulloblastoma: from tumor heterogeneity to diagnostic, prognostic, and translational applications.Frontiers in molecular neuroscience · 2026Review
- Elucidating Tumorigenesis Mechanisms and Assessing Immunotherapeutic Efficacy in Patient-Derived Medulloblastoma Organoid Models.International journal of biological sciences · 2026Article
- Exploring Novel Applications: Repositioning Clinically Approved Therapies for Medulloblastoma Treatment.Cancers · 2025Article
- The MYC-dependent lncRNA MB3 inhibits apoptosis in Group 3 Medulloblastoma by regulating the TGF-β pathway via HMGN5.Cell death & disease · 2025Article
- An imbalance between proliferation and differentiation underlies the development of microRNA-defective pineoblastoma.Genes & development · 2025Article
- Article
- Enhancer reprogramming: critical roles in cancer and promising therapeutic strategies.Cell death discovery · 2025Review
- In-depth inference of transcriptional regulatory networks reveals NPM1 as a therapeutic ribosomal regulator in MYC-amplified medulloblastoma.NPJ precision oncology · 2025Article
- Synergy of retinoic acid and BH3 mimetics in MYC(N)-driven embryonal nervous system tumours.British journal of cancer · 2024Article
- HIF-1 inactivation empowers HIF-2 to drive hypoxia adaptation in aggressive forms of medulloblastoma.Cell death discovery · 2024Article
- A Prognostic Methylation-Driven Two-Gene Signature in Medulloblastoma.Journal of molecular neuroscience : MN · 2024Article
- SALL4 is a CRL3Cell death and differentiation · 2024Article
- Combination drug screen identifies synergistic drug interaction of BCL-XL and class I histone deacetylase inhibitors in MYC-amplified medulloblastoma cells.Journal of neuro-oncology · 2024Article
- Circular extrachromosomal DNA promotes tumor heterogeneity in high-risk medulloblastoma.Nature genetics · 2023Article
- The identification of BCL-XL and MCL-1 as key anti-apoptotic proteins in medulloblastoma that mediate distinct roles in chemotherapy resistance.Cell death & disease · 2023Article
- Regulation of the stem‑like properties of estrogen receptor‑positive breast cancer cells through NR2E3/NR2C2 signaling.Experimental and therapeutic medicine · 2023Article
- Etiology of super-enhancer reprogramming and activation in cancer.Epigenetics & chromatin · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 11 institutions in 3 countries.
Alexandra GarancherInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Charles Y LinBaylor College of Medicine, Department of Molecular and Human Genetics, 1 Baylor Plaza, Houston, TX 77030, USA.
Morgane MorabitoInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Wilfrid RicherPSL Research University, Paris, France; Institut Curie, Paris 75248, France; INSERM U830, Paris 75248, France; Translational Research in Pediatric Oncology, Institut Curie SiRIC, Paris, France.
Nathalie RocquesInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Magalie LarcherInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Laure BihannicInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France; Department of Developmental Neurobiology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS325, Memphis, TN 38017, USA.
Kyle SmithDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS325, Memphis, TN 38017, USA.
Catherine MiquelDepartement de Neuropathologie, Hôpital Sainte-Anne, INSERM UMR_S1165, Université Paris Diderot, Sorbonne Paris Cité, Paris, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France.
Sophie LeboucherInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France.
Nirmitha I HerathInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Fanny DupuyInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Pascale VarletUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France; Departement de Neuropathologie, Hôpital Sainte-Anne, INSERM U894, Université Paris Diderot, Sorbonne Paris Cité, Paris, France.
Christine HaberlerInstitute of Neurology, Medical University of Vienna, Vienna, Austria.
Christine WalczakInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France; INSERM U1196, CNRS UMR9187, Centre Universitaire, Orsay 91405, France.
Nadine El TayaraInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France; INSERM U1196, CNRS UMR9187, Centre Universitaire, Orsay 91405, France.
Andreas VolkInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France; INSERM U1196, CNRS UMR9187, Centre Universitaire, Orsay 91405, France.
Stéphanie PugetUniversité Paris Descartes, Sorbonne Paris Cité, Paris, France; AP-HP, Hôpital Necker-Enfants Malades, Département Neurochirurgie pédiatrique, Paris, France.
François DozInstitut Curie, Paris 75248, France; Université Paris Descartes, Sorbonne Paris Cité, Paris, France; SIREDO Center (Care, innovation, Research in pediatric, adolescent and young adult oncology), Institut Curie, Paris, France.
Olivier DelattrePSL Research University, Paris, France; Institut Curie, Paris 75248, France; INSERM U830, Paris 75248, France; SIREDO Center (Care, innovation, Research in pediatric, adolescent and young adult oncology), Institut Curie, Paris, France.
Sabine DruillennecInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Olivier AyraultInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Robert J Wechsler-ReyaTumor Initiation & Maintenance Program, NCI-Designated Cancer Center, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA 92037, USA.
Alain EychèneInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France.
Franck BourdeautPSL Research University, Paris, France; Institut Curie, Paris 75248, France; INSERM U830, Paris 75248, France; Translational Research in Pediatric Oncology, Institut Curie SiRIC, Paris, France; SIREDO Center (Care, innovation, Research in pediatric, adolescent and young adult oncology), Institut Curie, Paris, France.
Paul A NorthcottDepartment of Developmental Neurobiology, St. Jude Children's Research Hospital, 262 Danny Thomas Place, MS325, Memphis, TN 38017, USA. Electronic address: paul.northcott@stjude.org.
Celio PouponnotInstitut Curie - Recherche, Laboratoire 110, Centre Universitaire, Orsay Cedex 91405, France; INSERM U1021, Centre Universitaire, Orsay 91405, France; CNRS UMR 3347, Centre Universitaire, Orsay 91405, France; Université Paris Sud-11, 91405 Orsay, France; PSL Research University, Paris, France. Electronic address: celio.pouponnot@curie.fr.
Centre National de la Recherche Scientifique · FRInserm · FRInstitut Curie · FRSt. Jude Children's Research Hospital · USUniversité Paris Sciences et Lettres · FRSorbonne Paris Cité · FRUniversité Paris-Sud · FRBaylor College of Medicine · USDélégation Paris 5 · FRDiscovery Institute · USMedical University of Vienna · AT
Funding
Tumor Microenvironment and Cancer ImmunologyP30CA030199 · NCI · SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE · PI ELENA B PASQUALE · 1985 to 2026
$107.2MIdentifying and Targeting Onocgenic MYC Enhancer Control in Pediatric TumorsR01CA215452 · NCI · BAYLOR COLLEGE OF MEDICINE · PI WESTBROOK, THOMAS · 2017 to 2021
$2.0MNCI NIH HHS P30 CA030199NCI NIH HHS R01 CA215452
Abstract
Cancer cells often express differentiation programs unrelated to their tissue of origin, although the contribution of these aberrant phenotypes to malignancy is poorly understood. An aggressive subgroup of medulloblastoma, a malignant pediatric brain tumor of the cerebellum, expresses a photoreceptor differentiation program normally expressed in the retina. We establish that two photoreceptor-specific transcription factors, NRL and CRX, are master regulators of this program and are required for tumor maintenance in this subgroup. Beyond photoreceptor lineage genes, we identify BCL-XL as a key transcriptional target of NRL and provide evidence substantiating anti-BCL therapy as a rational treatment opportunity for select MB patients. Our results highlight the utility of studying aberrant differentiation programs in cancer and their potential as selective therapeutic vulnerabilities.
Indexed as
AnimalsBasic-Leucine Zipper Transcription FactorsCell DifferentiationCerebellar NeoplasmsEye ProteinsHomeodomain ProteinsHumansMedulloblastomaMice, NudeRetinaTrans-ActivatorsTranscription, GeneticBasic-Leucine Zipper Transcription Factorscone rod homeobox proteinEye ProteinsHomeodomain ProteinsNRL protein, humanNrl protein, mouseTrans-ActivatorsapoptosisBCL2CRXMAFmedulloblastomaNRLphotoreceptorretina
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.